



Cynvec LLCSM to Present at the Cowen and Company 29th Annual Health Care Conference

New York, NY, March 9, 2009 – Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will present at the Cowen and Company 29th Annual Health Care Conference in Boston on Monday, March 16, 2009 at 4:00 p.m. ET.

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets overexpressed laminin receptors on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing therapies that may be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. The company's lead product, CYN 101, has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in ovarian cancer in the third quarter of 2009. The sindbis vector has also demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at www.cynvec.com.

Contacts:

Chris Smith (media)
SmithSolve
973-442-1555
chris.smith@smithsolve.com

Rhonda Chiger (investors)
Rx Communications Group
917-322-2569
rchiger@rxir.com